IMMU-114 / Gilead - LARVOL DELTA

Immunomedics announces potent anti-tumor activities with IMMU-114 in preclinical study in acute and chronic leukemia (GlobeNewswire) - "In a mouse model of human CLL that has similar HLA-DR and CD20 expression, IMMU-114 significantly improved median survival time (MST) of 19 days for the rituximab group to more than 42 days, even at doses as low as 50 µg (P<0.0001)."

Preclinical • Hematological Malignancies

Immunomedics: Q2 FY 2016 Results (Immunomedics) - Anticipated presentation of initial results of P1 trial (NCT01728207) in hematologic malignancies at ASH (Dec 3-6, 2016)

Anticipated P1 data • Hematological Malignancies

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (clinicaltrials.gov) - P1; N=30; Terminated; Sponsor: Immunomedics, Inc.; N=100 ➔ 30; Completed ➔ Terminated; Study was stopped due to insufficient efficacy and very slow accrual

Clinical • Enrollment change • Trial termination

Neutrophil Elastase and Alpha-1-Antitrypsin Binding in Monocyte Derived Microparticles (ATS 2019) - "Taken together, our findings suggest a novel function for HNE and AAT encapsulated in MPs in regards to inflammasome activation. Our patient data confirms this importance by correlating HNE bound to AAT with monocyte inflammation. Ongoing studies are focused on understanding this signaling pathway and effects on other inflammatory markers in microparticles.This work was supported by NIH RO1HL24325 to Sarkar and NIH RO1GM108928 to Sarkar/Wewers."

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (clinicaltrials.gov) - P1; N=100; Completed; Sponsor: Immunomedics, Inc.; Recruiting ➔ Completed

Clinical • Trial completion